Moderna, Inc. (MRNA)
| Market Cap | 10.82B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -3.12B |
| Shares Out | 390.73M |
| EPS (ttm) | -8.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,531,461 |
| Open | 25.58 |
| Previous Close | 25.49 |
| Day's Range | 25.38 - 27.75 |
| 52-Week Range | 22.28 - 48.92 |
| Beta | 1.11 |
| Analysts | Hold |
| Price Target | 33.91 (+22.42%) |
| Earnings Date | Nov 6, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $33.91, which is an increase of 22.42% from the latest price.
News
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership
A major vaccine producer came under pressure following a report federal health regulators plan to tighten vaccine approval rules. Meanwhile, an agreement with the world's most valuable company bolster...
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More
Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back. The S&P 500 and Nasdaq slid about 0.2%, while the Dow dropped 0.4%.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Moderna, Inc. (MRNA) Analyst/Investor Day Transcript
Moderna, Inc. ( MRNA) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Stéphane Bancel - CEO & Director Stephen Hoge - President Jerh Collins - Chief Technical Operations & Qua...
Moderna takes $1.5 billion loan, expects 10% revenue growth next year
Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash b...
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
Moderna to complete US mRNA manufacturing network with $140 million investment
Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturi...
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annu...
What Is Going On With Moderna Stock?
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over th...
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
Initiated stake: 500,000 shares, an estimated $12.91 million increase Post-trade Moderna position: 500,000 shares, valued at $12.91 million Moderna now accounts for 1.23% of Telemark's reportable AUM,...
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
Moderna, Inc. ( MRNA) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Ch...
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.
Moderna trims top end of full-year forecast on weak COVID vaccine sales
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating...
Moderna Stock Is Sliding Monday: What's Going On?
Moderna Inc (NASDAQ:MRNA) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational ...
Moderna: Focus On Cancer Vaccines, Not Buyout
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRN...
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here's what investors need to know.
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine...